Preeclampsia in pregnancy affecting the stemness and differentiation potency of haematopoietic stem cell of the umbilical cord blood.
Adult
Antigens, CD34
Blood Banks
Case-Control Studies
Cell Count
Cell Differentiation
Colony-Forming Units Assay
Cord Blood Stem Cell Transplantation
Cross-Sectional Studies
Female
Fetal Blood
/ cytology
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
/ cytology
Humans
Pre-Eclampsia
/ blood
Pregnancy
Colony forming unit (CFU)
Haematopoietic stem cell (HSC), preeclampsia (PE), Total nucleated cell (TNC)
Umbilical cord blood (UCB)
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
10 Jul 2020
10 Jul 2020
Historique:
received:
03
12
2019
accepted:
01
07
2020
entrez:
12
7
2020
pubmed:
12
7
2020
medline:
2
3
2021
Statut:
epublish
Résumé
Umbilical cord blood (UCB) has been proposed as the potential source of haematopoietic stem cells (HSC) for allogeneic transplantation. However, few studies have shown that a common disease in pregnancy such as preeclampsia would affect the quality of UCB-HSC. Total nucleated cell count (TNC) is an important parameter that can be used to predict engraftment including UCB banking. Colony forming unit (CFU) assay is widely used as an indicator to predict the success of engraftment, since direct quantitative assay for HSC proliferation is unavailable. The aim of this study is to investigate the effects of preeclampsia in pregnancy on the stemness and differentiation potency of UCB-HSC. Mononuclear cells (MNC) were isolated from UCB and further enriched for CD34+ cells using immune-magnetic method followed by CFU assay. A panel of HSC markers including differentiated haematopoietic markers were used to confirm the differentiation ability of UCB-HSC by flow cytometry analysis. The HSC progenitor's colonies from the preeclampsia group were significantly lower compared to the control. This correlates with the low UCB volume, TNC and CD34+ cells count. In addition, the UCB-enriched CD34+ population were lymphoid progenitors and capable to differentiate into natural killer cells and T-lymphocytes. These findings should be taken into consideration when selecting UCB from preeclamptic mothers for banking and predicting successful treatment related to UCB transplant.
Sections du résumé
BACKGROUND
BACKGROUND
Umbilical cord blood (UCB) has been proposed as the potential source of haematopoietic stem cells (HSC) for allogeneic transplantation. However, few studies have shown that a common disease in pregnancy such as preeclampsia would affect the quality of UCB-HSC. Total nucleated cell count (TNC) is an important parameter that can be used to predict engraftment including UCB banking. Colony forming unit (CFU) assay is widely used as an indicator to predict the success of engraftment, since direct quantitative assay for HSC proliferation is unavailable. The aim of this study is to investigate the effects of preeclampsia in pregnancy on the stemness and differentiation potency of UCB-HSC.
METHODS
METHODS
Mononuclear cells (MNC) were isolated from UCB and further enriched for CD34+ cells using immune-magnetic method followed by CFU assay. A panel of HSC markers including differentiated haematopoietic markers were used to confirm the differentiation ability of UCB-HSC by flow cytometry analysis.
RESULTS/ DISCUSSION
UNASSIGNED
The HSC progenitor's colonies from the preeclampsia group were significantly lower compared to the control. This correlates with the low UCB volume, TNC and CD34+ cells count. In addition, the UCB-enriched CD34+ population were lymphoid progenitors and capable to differentiate into natural killer cells and T-lymphocytes.
CONCLUSION
CONCLUSIONS
These findings should be taken into consideration when selecting UCB from preeclamptic mothers for banking and predicting successful treatment related to UCB transplant.
Identifiants
pubmed: 32650736
doi: 10.1186/s12884-020-03084-7
pii: 10.1186/s12884-020-03084-7
pmc: PMC7350629
doi:
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
399Références
Blood. 2000 Oct 15;96(8):2717-22
pubmed: 11023503
Transfus Apher Sci. 2010 Dec;43(3):315-320
pubmed: 20971685
Mol Cell Biol. 1994 Jul;14(7):4342-9
pubmed: 8007943
Stem Cells. 2005 Nov-Dec;23(10):1560-70
pubmed: 16081669
J Obstet Gynaecol Res. 2010 Feb;36(1):52-7
pubmed: 20178527
Br J Haematol. 1999 Jul;106(1):128-32
pubmed: 10444175
Bone Marrow Transplant. 2007 May;39(9):515-21
pubmed: 17334379
Am J Obstet Gynecol. 2007 Jan;196(1):68.e1-6
pubmed: 17240239
Blood. 1995 Nov 15;86(10):3745-53
pubmed: 7579341
J Vis Exp. 2010 Dec 18;(46):
pubmed: 21252854
Blood Cancer J. 2011 Sep;1(9):e36
pubmed: 22829197
Acta Haematol. 2001;105(2):71-6
pubmed: 11408707
N Engl J Med. 1992 Apr 2;326(14):927-32
pubmed: 1542342
Pediatr Res. 1998 Mar;43(3):349-54
pubmed: 9505273
Transfusion. 2004 Feb;44(2):262-7
pubmed: 14962318
Am J Clin Pathol. 2011 Nov;136(5):721-6
pubmed: 22031310
Haematologica. 1996 Sep-Oct;81(5):404-9
pubmed: 8952152
Cytotechnology. 2015 May;67(3):387-96
pubmed: 25373337
Blood. 2013 Jul 25;122(4):491-8
pubmed: 23673863
Am J Obstet Gynecol. 2003 Feb;188(2):503-9
pubmed: 12592263
Blood. 2002 Sep 1;100(5):1611-8
pubmed: 12176879
Ann Hematol. 2006 Jun;85(6):381-5
pubmed: 16534595
Leukemia. 1998 May;12(5):728-34
pubmed: 9593271
Rev Clin Exp Hematol. 2001 Jun;5(2):87-99
pubmed: 11486656
Transfusion. 2006 Oct;46(10):1803-12
pubmed: 17002638
Am J Obstet Gynecol. 2001 Sep;185(3):725-9
pubmed: 11568804
Biol Blood Marrow Transplant. 2001;7(12):635-45
pubmed: 11787526
N Engl J Med. 2000 Jun 22;342(25):1846-54
pubmed: 10861319
N Engl J Med. 2004 Nov 25;351(22):2276-85
pubmed: 15564544
N Engl J Med. 1997 Aug 7;337(6):373-81
pubmed: 9241126
Stem Cells. 1995 Mar;13(2):158-66
pubmed: 7540469